24-month follow-up of Phase IIb Diamyd® clinical trial indicates continued similar progression after 15 months
50 out of the 109 individuals in DIAGNODE-2 who were included in an extension study have now been followed for a total of 24 months. The actively treated individuals carrying HLA DR3-DQ2, in total 15 individuals, followed their expected trajectory from 15 to 24 month, showing no indication of diminishing treatment effect compared to their progression up to to 15 months. As also expected, safety at 24 months looks good with no difference in adverse events between actively treated and placebo treated individuals.As was disclosed in April 2021, no formal statistical analysis has been